We are live on ! Find out more
RAPT

RAPT Therapeutics

Delisted

RAPT was delisted on the 2nd of March, 2026.

99 hedge funds and large institutions have $1.02B invested in RAPT Therapeutics in 2021 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 28 increasing their positions, 34 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,497% more call options, than puts

Call options by funds: $12.9M | Put options by funds: $495K

25% more capital invested

Capital invested by funds: $815M → $1.02B (+$205M)

11% more funds holding in top 10

Funds holding in top 10: 910 (+1)

0.59% more ownership

Funds ownership: 11.19%11.78% (+0.59%)

7% less funds holding

Funds holding: 10699 (-7)

18% less repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 34

19% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 21

Holders
99
Holders Change
-7
Holders Change %
-6.6%
% of All Funds
1.52%
Holding in Top 10
10
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+11.11%
% of All Funds
0.15%
New
17
Increased
28
Reduced
34
Closed
21
Calls
$12.9M
Puts
$495K
Net Calls
+$12.4M
Net Calls Change
+$9.69M
Name Holding Trade Value Shares
Change
Change in
Stake
T. Rowe Price Associates
1
T. Rowe Price Associates
Maryland
$145M +$1.52M +5,689 +1%
PA
2
Perceptive Advisors
New York
$108M +$668K +2,500 +0.7%
Fidelity Investments
3
Fidelity Investments
Massachusetts
$82.6M +$37M +138,463 +97%
BlackRock
4
BlackRock
New York
$66.2M -$3.25M -12,169 -5%
PM
5
Ponoi Management
California
$58.7M
CG
6
Column Group
California
$51.5M
Wellington Management Group
7
Wellington Management Group
Massachusetts
$50.3M -$4.57M -17,110 -9%
KXA
8
KPCB XV Associates
California
$47.6M
State Street
9
State Street
Massachusetts
$45.7M +$30M +112,368 +261%
Vanguard Group
10
Vanguard Group
Pennsylvania
$44.3M +$4.26M +15,933 +12%
KCM
11
Kingdon Capital Management
New York
$42.2M
Morgan Stanley
12
Morgan Stanley
New York
$36.7M +$7.89M +29,516 +31%
AI
13
Alphabet Inc
California
$23.1M -$2.76M -10,311 -12%
ROTUOC
14
Regents of the University of California
California
$16.3M -$5.51M -20,631 -27%
EC
15
Euclidean Capital
New York
$15.9M -$6.76M -25,284 -32%
GTC
16
Ghost Tree Capital
New York
$12.9M +$3.34M +12,500 +40%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$12.6M -$95.2K -356 -0.8%
Deutsche Bank
18
Deutsche Bank
Germany
$11.5M +$9.92M +37,130 +2,008%
Two Sigma Advisers
19
Two Sigma Advisers
New York
$8.37M -$768K -2,875 -9%
O
20
OrbiMed
New York
$7.97M +$7.25M +27,125 New
Dimensional Fund Advisors
21
Dimensional Fund Advisors
Texas
$7.94M +$3.49M +13,069 +94%
Northern Trust
22
Northern Trust
Illinois
$7.88M -$83.7K -313 -1%
ACM
23
Atika Capital Management
New York
$7.72M +$7.03M +26,286 New
HM
24
HealthCor Management
New York
$6.66M -$110K -413 -2%
PIM
25
Ponoi II Management
California
$5.34M

RAPT Hedge Fund Activity: Q4 2021 in Review

99 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in RAPT Therapeutics (RAPT) for Q4 2021, worth a combined $1.02B — up 25% from $815M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of RAPT and 17 opened new positions — a net loss of 4 holders — while 34 trimmed existing stakes and 28 added.

The largest buyer was Fidelity Investments, adding an estimated $37M. The largest seller was Millennium Management, cutting an estimated $15.6M.

  • 99 institutional investors held RAPT Therapeutics (RAPT) as of Q4 2021, down from 106 in Q3 2021.
  • Funds reported $1.02B of RAPT Therapeutics stock for Q4 2021, up 25% quarter-over-quarter.
  • 17 funds opened new RAPT Therapeutics positions in Q4 2021 and 21 closed out, a net change of -4 holders.
  • The largest RAPT Therapeutics buyer in Q4 2021 was Fidelity Investments, an estimated $37M added.
  • The largest RAPT Therapeutics seller in Q4 2021 was Millennium Management, an estimated $15.6M sold.

Based on aggregated 13F filings for Q4 2021.